DOCSLIB.ORG

Therapeutic Apheresis for Patients with Cancer Laura S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Therapeutic Apheresis for Patients with Cancer Laura S Therapeutic apheresis is an important treatment modality frequently used to manage specific complications in patients with underlying malignant disease. Ray Paul. Dark Shadows, 2010. Acrylic, latex, enamel on canvas, 30" × 30". Therapeutic Apheresis for Patients With Cancer Laura S. Connelly-Smith, MBBCh, DM, and Michael L. Linenberger, MD Background: Disease complications associated with certain malignancies may be mediated by cells or soluble molecules that traffic in the bloodstream. Because of this, therapeutic apheresis (TA) methodologies have been used to selectively remove or manipulate specific molecules, antibodies, or cellular elements to treat the underlying pathological process. For some disorders, TA is utilized as a rapid-acting and short-term adjunct to conventional chemotherapy or immunotherapy. For others, a series of scheduled treatments is recommended for optimal management. In all cases, the risks, benefits, and costs must be strongly considered. Methods: The current literature and published guidelines were reviewed to summarize the use of TA in the management of certain complications of cancer. Results: Although TA is relatively safe and useful as a first-line or salvage modality for some disorders, few prospective, randomized clinical trials exist and the majority of evidence is derived from observational studies. Expert-based, clinical practice guidelines have been developed to inform hematology/oncology professionals and apheresis physicians about the efficacy and limitations of TA for malignancy-related indications. Conclusions: Certain oncological conditions respond to TA and consensus guidelines are available to support clinical decision-making. However, well-designed, prospective intervention trials are needed to better define the role of TA for a variety of disorders. Introduction In general, TA is a relatively safe procedure; however, Therapeutic apheresis (TA) is used to treat certain insufficient clinical evidence to support the econom- disease complications in patients with cancer with ic cost of TA can be a limitation to its use for some the intention of removing or manipulating a specific conditions. Evidence-based clinical practice guidelines molecule, antibody, or cellular element thought to be have been developed and periodically updated by the contributing to the underlying pathological process. American Society for Apheresis (ASFA) to help sup- port the decision making of health care professionals regarding the use of TA.1 From the Seattle Cancer Care Alliance (LSC-S, MLL), the Division of In this article, we provide a brief overview of TA Hematology (LSC-S, MLL) of the School of Medicine at the University of Washington, and the Fred Hutchinson Cancer Research Center and discuss considerations for its use as a treatment (MLL), Seattle, Washington. option. The apheresis modalities most commonly Address correspondence to Laura S. Connelly-Smith, MBBCh, DM, used to treat patients with cancer include the ther- Seattle Cancer Care Alliance, 825 East Eastlake Avenue, Seattle, WA, apeutic plasma exchange (TPE), leukocytapheresis, 98109. E-mail: [email protected] extracorporeal photopheresis (ECP), thrombocyta- Submitted June 15, 2014; accepted October 8, 2014. pheresis, and erythrocytapheresis. Herein, we review No significant relationships exist between the authors and the companies/organizations whose products or services may be the known oncological diseases or associations for referenced in this article. which specific TA modalities have been successfully 60 Cancer Control January 2015, Vol. 22, No. 1 Table 1. — Indications for Therapeutic Apheresis in Patients With Cancer Therapeutic Indication Disease Condition Categorya Gradeb Apheresis Modality Therapeutic plasma Hyperviscosity in Symptomatic I 1B exchange (TPE) monoclonal gammopathies Prophylaxis for rituximab I 1C Myeloma kidney/myeloma cast nephropathy II 2B Paraneoplastic neurological syndromes Lambert Eaton myasthenic syndrome II 2C (see also Table 4) Other paraneoplastic III 2C neurological syndromes Hematopoietic stem cell transplantation– Refractory III 2C associated thrombotic microangiopathy Therapeutic Hyperleukocytosis With leukostasis clinical signs I 1B leukocytapheresis and symptoms Prophylaxis (asymptomatic) III 2C Extracorporeal Cutaneous T-cell lymphoma, Erythrodermic I 1B photopheresis mycosis fungoides, Sézary syndrome Nonerythrodermic III 2C GVHD Skin chronic GVHD II 1B Skin acute GVHD II 1C Non–skin acute and chronic GVHD III 2B Thrombocytapheresis Thrombocytosis with Symptomatic II 2C myeloproliferative neoplasm Prophylactic III 2C Erythrocytapheresis Polycythemia vera/primary erythrocytosis I 1B aDenotes American Society for Apheresis category. bDenotes American Society for Apheresis grade. For more information, refer to Tables 2 and 3. GVHD = graft-vs-host disease. Data from reference 1. employed. Table 1 summarizes these modalities, clin- anticoagulated blood during the procedure. The fluid ical conditions, and the most recent ASFA guideline returned back to the patient contains the undesired recommendations.1 However, well-designed, prospec- blood components along with anticoagulant, crystal- tive intervention trials are still required to fully define loid, and/or colloid solutions. Membrane filtration the role of TA for many of these disorders. systems separate and collect plasma on a principle TA plays an important role in the management similar to hemodialysis and ultrafiltration, namely of various oncological diseases. It is a procedure in using membranes permeable to high-molecular-weight which blood is separated from a patient, a portion proteins but not cellular elements. The predominant of which is then removed or otherwise manipulated instruments and methodologies used for TA proce- and the remainder is then returned to the patient. TA dures in the United States utilize centrifugation.2 procedures include TPE (in which plasma is replaced with a colloid or crystalloid solution) and modalities Clinical Adverse Events that selectively remove and dispose of plasma solutes TA can be associated with minimal to potentially fa- (plasmapheresis), white blood cells (WBCs; leukocy- tal adverse events, although the overall incidence is tapheresis), or platelets (thrombocytapheresis). ECP relatively low (5%–12%).3 Hypersensitivity reactions is a type of leukocytapheresis procedure whereby the due to plasma or blood product replacement fluid can removed white cells are manipulated prior to being range from urticarial to anaphylactoid-type reactions. reinfused into the patient. Hypocalcemia secondary to citrate anticoagulant can Apheresis procedures can utilize centrifugation to manifest as paresthesia, nausea, vomiting, lighthead- separate blood components into layers within a rapid- edness, and twitching. Hypovolemia due to fluid shifts ly rotating separation chamber based on their relative or vasovagal reaction may manifest as hypotension, density — with red blood cells (RBCs) being the most muscle cramps, and headache. Rare, serious adverse dense, plasma the least dense — and intermediate events requiring the procedure to be interrupted or layers, moving from the axis of rotation outward and abandoned (0.8% incidence) or resulting in fatality consisting of platelet-rich plasma, lymphocytes, and (≤ 0.5%) due to cardiovascular events can include granulocytes.1 Specific kits are designed to remove arrhythmia or ischemia, pulmonary edema, pulmo- RBCs or plasma or cells of intermediate density from nary embolism, and respiratory arrest; neurological January 2015, Vol. 22, No. 1 Cancer Control 61 complications can also occur and may include tetany, of peripheral veins compared with CVCs has not been seizures, and cerebrovascular accident.3 Hemorrhage, explained by differences in patient age, sex, the me- thrombosis, and infection are uncommon. The causes dian number of treatments per patient, or the type of death have included respiratory arrest, anaphylaxis, of apheresis procedure.13 Nevertheless, peripheral and catheter-associated sepsis.3 venous access is underutilized in TA procedures and is the access of choice because it is associated with a Vascular Access lower risk of infection relative to CVCs and placement The majority of apheresis procedures are centrifuga- can be done immediately with a low risk of other tion based; therefore, they require withdrawal blood serious complications.10 Complications of peripheral flow rates of 50 to 150 mL/minute.4-7 Peripheral an- cannulation include risk of infection, venous infiltra- tecubital veins that can be cannulated using 16- to tion, patient discomfort, thrombosis and sclerosis of 18-gauge polytetrafluoroethylene- or silicone-coat- veins, and the loss of future venous access. Peripheral ed, dialysis-type steel needles will accommodate vein access for TA is not a viable option in children blood flow rates of 80 mL/minute and is adequate due to their small venous caliber. for centrifugation techniques. By contrast, filtration Peripherally inserted central catheters are too therapies require a blood flow rate of at least 150 to small in caliber (4–5 Fr) to accommodate the neg- 200 mL/minute, which is unsuitable for antecubital ative pressure and blood flow rates required for TA veins.4-7 Other considerations specific to TA include procedures.10 Arteriovenous fistulas and grafts are vi- whether the treatment relies on discontinuous, se- able options for long-term access when the treatment quential blood exchange cycles (1 lumen is sufficient) duration is
Load more

Recommended publications
  • Guidelines for Transfusions
    Guidelines for Transfu- sion Prepared by: Community Transfusion Committee Lincoln, Nebraska CHAIR: Aina Silenieks, MD MEMBERS: L. Bausch, M.D. R. Burton, M.D. S. Dunder, M.D. D. Voigt, M.D. B. J. Wilson, M.D. COMMUNITY Becky Croner REPRESENTATIVES: Ellen DiSalvo Christa Engel Phyllis Ericson Kelly Gillaspie Pat Gilles Vic Grdina Jessica Henrichs Kelly Jensen Laurel McReynolds Christina Nickel Angela Novotny Kelley Thiemann Janet Wachter Jodi Wikoff Guidelines For Transfusion Community Transfusion Committee INTRODUCTION The Community Transfusion Committee is a multidisciplinary group that meets to monitor blood utilization practices, establish guidelines for transfusion and discuss relevant transfusion related topics. It is comprised of physicians from local hospitals, invited guests, and community representatives from the hospitals’ transfusion services, nursing services, perfusion services, health information management, and the Nebraska Community Blood Bank. These Guidelines for Transfusion are reviewed and revised biannually by the Community Trans- fusion Committee to ensure that the industry’s most current practices are promoted. The Guidelines are the standard by which utilization practices are evaluated. They are also de- signed to provide helpful information to assist physicians to provide appropriate blood compo- nent therapy to patients. Appendices have been added for informational purposes and are not to be used as guidance for clinical decision making. ADULT RED CELLS A. Indications 1. One of the following a. Hypovolemia and hypoxia (signs/symptoms: syncope, dyspnea, postural hypoten- sion, tachycardia, angina, or TIA) secondary to surgery, trauma, GI tract bleeding, or intravascular hemolysis, OR b. Evidence of acute loss of 15% of total blood volume or >750 mL blood loss, OR c.
    [Show full text]
  • 27. Clinical Indications for Cryoprecipitate And
    27. CLINICAL INDICATIONS FOR CRYOPRECIPITATE AND FIBRINOGEN CONCENTRATE Cryoprecipitate is indicated in the treatment of fibrinogen deficiency or dysfibrinogenaemia.1 Fibrinogen concentrate is licenced for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenaemia and hypofibrinogenaemia,2 and is currently funded under the National Blood Agreement. Key messages y Fibrinogen is an essential component of the coagulation system, due to its role in initial platelet aggregation and formation of a stable fibrin clot.3 y The decision to transfuse cryoprecipitate or fibrinogen concentrate to an individual patient should take into account the relative risks and benefits.3 y The routine use of cryoprecipitate or fibrinogen concentrate is not advised in medical or critically ill patients.2,4 y Cryoprecipitate or fibrinogen concentrate may be indicated in critical bleeding if fibrinogen levels are not maintained using FFP. In the setting of major obstetric haemorrhage, early administration of cryoprecipitate or fibrinogen concentrate may be necessary.3 Clinical implications y The routine use of cryoprecipitate or fibrinogen concentrate in medical or critically ill patients with coagulopathy is not advised. The underlying causes of coagulopathy should be identified; where transfusion is considered necessary, the risks and benefits should be considered for each patient. Specialist opinion is advised for the management of disseminated intravascular coagulopathy (MED-PP18, CC-PP7).2,4 y Cryoprecipitate or fibrinogen concentrate may be indicated in critical bleeding if fibrinogen levels are not maintained using FFP. In patients with critical bleeding requiring massive transfusion, suggested doses of blood components is 3-4g (CBMT-PP10)3 in adults or as per the local Massive Transfusion Protocol.
    [Show full text]
  • Factors Affecting Mobilization of Peripheral Blood Progenitor Cells in Patients with Lymphoma’
    Vol. 4, 311-316, February 1998 Clinical Cancer Research 311 Factors Affecting Mobilization of Peripheral Blood Progenitor Cells in Patients with Lymphoma’ Craig H. Moskowitz,2 Jill R. Glassman, (median, 13 versus 22 days; P 0.06). Patients who received 1l cycles of chemotherapy prior to PBPC mobilization David Wuest, Peter Maslak, Lilian Reich, tended to have delayed platelet recovery to >20,090/&l and Anthony Gucciardo, Nancy Coady-Lyons, to require more platelet transfusions than less extensively Andrew D. Zelenetz, and Stephen D. Nimer pretreated patients (median, 13.5 versus 23.5 days; P 0.15; Division of Hematologic Oncology, Department of Medicine median number of platelet transfusion episodes, 13 versus 9; [C. H. M., D. W., P. M., L. R., A. G., N. C-L., A. D. Z., S. D. N.] and P = 0.17). Department of Biostatistics [J. R. G.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021 These data suggest that current strategies to mobilize PBPCs may be suboptimal in patients who have received either stem cell-toxic chemotherapy or 11 cycles of chem- ABSTRACT otherapy prior to PBPC mobilization. Alternative ap- The objective of this study was to identify factors asso- proaches, such as ex vivo expansion or the use of other ciated with poor mobilization of peripheral blood progenitor growth factors in addition to G-CSE, may improve mobili- cells (PBPCs) or delayed platelet engraftment after high- zation of progenitor cells for PBPC transplantation. dose therapy and autologous stem cell transplantation in patients with lymphoma. INTRODUCTION Fifty-eight patients with Hodgkin’s disease or non- The use of high-dose chemoradiotherapy supported by Hodgkin’s lymphoma underwent PBPC transplantation as cryopreserved autologous hematopoietic progenitor cells is ef- the “best available therapy” at Memorial Sloan-Kettering fective in treating relapsed HD3 and NHL; a high complete Cancer Center (New York, NY) between 1993 and 1995.
    [Show full text]
  • Fluid Resuscitation Therapy for Hemorrhagic Shock
    CLINICAL CARE Fluid Resuscitation Therapy for Hemorrhagic Shock Joseph R. Spaniol vides a review of the 4 types of shock, the 4 classes of Amanda R. Knight, BA hemorrhagic shock, and the latest research on resuscita- tive fluid. The 4 types of shock are categorized into dis- Jessica L. Zebley, MS, RN tributive, obstructive, cardiogenic, and hemorrhagic Dawn Anderson, MS, RN shock. Hemorrhagic shock has been categorized into 4 Janet D. Pierce, DSN, ARNP, CCRN classes, and based on these classes, appropriate treatment can be planned. Crystalloids, colloids, dopamine, and blood products are all considered resuscitative fluid treat- ment options. Each individual case requires various resus- ■ ABSTRACT citative actions with different fluids. Healthcare Hemorrhagic shock is a severe life-threatening emergency professionals who are knowledgeable of the information affecting all organ systems of the body by depriving tissue in this review would be better prepared for patients who of sufficient oxygen and nutrients by decreasing cardiac are admitted with hemorrhagic shock, thus providing output. This article is a short review of the different types optimal care. of shock, followed by information specifically referring to hemorrhagic shock. The American College of Surgeons ■ DISTRIBUTIVE SHOCK categorized shock into 4 classes: (1) distributive; (2) Distributive shock is composed of 3 separate categories obstructive; (3) cardiogenic; and (4) hemorrhagic. based on their clinical outcome. Distributive shock can be Similarly, the classes of hemorrhagic shock are grouped categorized into (1) septic; (2) anaphylactic; and (3) neu- by signs and symptoms, amount of blood loss, and the rogenic shock. type of fluid replacement. This updated review is helpful to trauma nurses in understanding the various clinical Septic shock aspects of shock and the current recommendations for In accordance with the American College of Chest fluid resuscitation therapy following hemorrhagic shock.
    [Show full text]
  • Cryosupernatant Plasma
    Cryosupernatant Plasma APPLICABILITY: This document applies to Other Names: Cryopoor Plasma AHS, Covenant Health, and all other health Class: Human blood component care professionals involved in the transfusion of blood components and products in Alberta INTRAVENOUS OTHER Intermittent Continuous ROUTES DIRECT IV SC IM OTHER Infusion Infusion Acceptable No Yes No No No N/A Routes* * Professionals performing these restricted activities have received authorization from their regulatory college and have the knowledge and skill to perform the skill competently. DESCRIPTION OF PRODUCT: . Cryosupernatant Plasma (CSP) is prepared from slowly thawed Frozen Plasma that is centrifuged to separate the insoluble cryopreciptate from the plasma. The remaining Cryosupernatant plasma is then refrozen. The approximate volume of a unit is 273 mL . CSP has reduced levels of Factor VIII and von Willebrand Factor (vWF), and does not contain measurable amounts of Factor VIII or fibrinogen. Donors are screened and blood donations are tested for: . ABO/Rh and clinically significant antibodies . Antibodies to human immunodeficiency virus (HIV-1 and HIV-2), hepatitis C virus (HCV), human T-cell lymphotropic virus type I and II (HTLV-I/II), hepatitis B core antigen (HBcore) . Hepatitis B Surface Antigen (HBsAg) . Presence of viral RNA (HIV-1 and HCV) and viral DNA (hepatitis B virus (HBV)) . Syphilis AVAILABILITY: . Not all laboratories/transfusion services stock CSP. Product is stored frozen, and as a result requires preparation time prior to issuing. Patient blood type should be determined when possible to allow for ABO specific/compatible plasma transfusion INDICATIONS FOR USE: . Plasma exchange in patients with Thrombotic Thrombocytopenic Purpura (TTP) or Hemolytic Uremic Syndrome (HUS).
    [Show full text]
  • Apheresis Donation This Quick Reference Guide Will Help You Identify the Best Donation for Your Unique Blood Type
    Apheresis Donation This quick reference guide will help you identify the best donation for your unique blood type. Donors now have the opportunity to make an apheresis (ay-fur-ee-sis) donation and donate just platelets, red cells, or plasma at blood drives. These individual components are vital for local patients in need. Platelets Control Bleeding Red Cells Deliver Oxygen Plasma transports blood cells & controls bleeding Donation Type Blood Types Requirements Donation Time A+, B+, O+ Over 75% of population has one of these blood types. Platelet Donation: Be healthy, weigh at least 114 lbs 2 hours cancer & surgery patients no aspirin for 48 hours Platelets only last five days after donation so the need is constant. O-, O+, A-, B- Special height, weight, Double Red: O-Negative is the 1 hour and hematocrit requirements. surgery, trauma patients, universal red cell donor. +25 min Please call us or see a staff member accident, & burn victims Only 17% of population has one of these negative blood types Plasma: AB+, AB- Trauma patients, burn Universal Plasma Donors 1 hour Be healthy, weigh at least 114 lbs victims, & patients with +30 min serious illness or injuries Only 4% of population How Apheresis works: Blood is drawn from the donor’s arm and the components are separated. Only the components being donated are collected while the remaining components are safely returned to the donor How to Schedule an Appointment: Please call 800-398-7888 or visit schedule.bloodworksnw.org. Walk-ins are also welcome at some blood drives, so be sure to ask our staff when you stop in.
    [Show full text]
  • Guidelines for Transfusion and Patient Blood Management, and Discuss Relevant Transfusion Related Topics
    Guidelines for Transfusion and Community Transfusion Committee Patient Blood Management Community Transfusion Committee CHAIR: Aina Silenieks, M.D., [email protected] MEMBERS: A.Owusu-Ansah, M.D. S. Dunder, M.D. M. Furasek, M.D. D. Lester, M.D. D. Voigt, M.D. B. J. Wilson, M.D. COMMUNITY Juliana Cordero, Blood Bank Coordinator, CHI Health Nebraska Heart REPRESENTATIVES: Becky Croner, Laboratory Services Manager, CHI Health St. Elizabeth Mackenzie Gasper, Trauma Performance Improvement, Bryan Medical Center Kelly Gillaspie, Account Executive, Nebraska Community Blood Bank Mel Hanlon, Laboratory Specialist - Transfusion Medicine, Bryan Medical Center Kyle Kapple, Laboratory Quality Manager, Bryan Medical Center Lauren Kroeker, Nurse Manager, Bryan Medical Center Christina Nickel, Clinical Laboratory Director, Bryan Medical Center Rachael Saniuk, Anesthesia and Perfusion Manager, Bryan Medical Center Julie Smith, Perioperative & Anesthesia Services Director, Bryan Medical Center Elaine Thiel, Clinical Quality Improvement/Trans. Safety Officer, Bryan Med Center Kelley Thiemann, Blood Bank Lead Technologist, CHI Health St. Elizabeth Cheryl Warholoski, Director, Nebraska Operations, Nebraska Community Blood Bank Jackie Wright, Trauma Program Manager, Bryan Medical Center CONSULTANTS: Jed Gorlin, M.D., Innovative Blood Resources [email protected] Michael Kafka, M.D., LifeServe Blood Center [email protected] Alex Smith, D.O., LifeServe Blood Center [email protected] Nancy Van Buren, M.D., Innovative
    [Show full text]
  • Blood Product Modifications: Leukofiltration, Irradiation and Washing
    Blood Product Modifications: Leukofiltration, Irradiation and Washing 1. Leukocyte Reduction Definitions and Standards: o Process also known as leukoreduction, or leukofiltration o Applicable AABB Standards, 25th ed. Leukocyte-reduced RBCs At least 85% of original RBCs < 5 x 106 WBCs in 95% of units tested . Leukocyte-reduced Platelet Concentrates: At least 5.5 x 1010 platelets in 75% of units tested < 8.3 x 105 WBCs in 95% of units tested pH≥6.2 in at least 90% of units tested . Leukocyte-reduced Apheresis Platelets: At least 3.0 x 1011 platelets in 90% of units tested < 5.0 x 106 WBCs 95% of units tested pH≥6.2 in at least 90% of units tested Methods o Filter: “Fourth-generation” filters remove 99.99% WBCs o Apheresis methods: most apheresis machines have built-in leukoreduction mechanisms o Less efficient methods of reducing WBC content . Washing, deglycerolizing after thawing a frozen unit, centrifugation . These methods do not meet requirement of < 5.0 x 106 WBCs per unit of RBCs/apheresis platelets. Types of leukofiltration/leukoreduction o “Pre-storage” . Done within 24 hours of collection . May use inline filters at time of collection (apheresis) or post collection o “Pre-transfusion” leukoreduction/bedside leukoreduction . Done prior to transfusion . “Bedside” leukoreduction uses gravity-based filters at time of transfusion. Least desirable given variability in practice and absence of proficiency . Alternatively performed by transfusion service prior to issuing Benefits of leukoreduction o Prevention of alloimmunization to donor HLA antigens . Anti-HLA can mediate graft rejection and immune mediated destruction of platelets o Leukoreduced products are indicated for transplant recipients or patients who are likely platelet transfusion dependent o Prevention of febrile non-hemolytic transfusion reactions (FNHTR) .
    [Show full text]
  • 45 Part 606—Current Good Man- Ufacturing Practice
    Food and Drug Administration, HHS Pt. 606 a presentation. The presiding officer ucts approved under § 601.91, the re- may, as a matter of discretion, permit strictions would no longer apply when questions to be submitted to the pre- FDA determines that safe use of the bi- siding officer for response by a person ological product can be ensured making a presentation. through appropriate labeling. FDA also (f) Judicial review. The Commissioner retains the discretion to remove spe- of Food and Drugs’ decision constitutes cific postapproval requirements upon final agency action from which the ap- review of a petition submitted by the plicant may petition for judicial re- sponsor in accordance with § 10.30 of view. Before requesting an order from a this chapter. court for a stay of action pending re- view, an applicant must first submit a PART 606—CURRENT GOOD MAN- petition for a stay of action under § 10.35 of this chapter. UFACTURING PRACTICE FOR BLOOD AND BLOOD COMPO- [67 FR 37996, May 31, 2002, as amended at 70 NENTS FR 14984, Mar. 24, 2005] § 601.93 Postmarketing safety report- Subpart A—General Provisions ing. Sec. Biological products approved under 606.3 Definitions. this subpart are subject to the post- marketing recordkeeping and safety Subpart B—Organization and Personnel reporting applicable to all approved bi- ological products. 606.20 Personnel. § 601.94 Promotional materials. Subpart C—Plant and Facilities For biological products being consid- 606.40 Facilities. ered for approval under this subpart, unless otherwise informed by the agen- Subpart D—Equipment cy, applicants must submit to the agency for consideration during the 606.60 Equipment.
    [Show full text]
  • Intraoperative Fluid Therapy and Pulmonary Complications
    ■ Feature Article Intraoperative Fluid Therapy and Pulmonary Complications KRZYSZTOF SIEMIONOW, MD; JACEK CYWINSKI, MD; KRZYSZTOF KUSZA, MD, PHD; ISADOR LIEBERMAN, MD, MBA, FRCSC abstract Full article available online at ORTHOSuperSite.com. Search: 20120123-06 The purpose of this study was to evaluate the effects of intraoperative fl uid therapy on length of hospital stay and pulmonary complications in patients undergoing spine surgery. A total of 1307 patients were analyzed. Sixteen pulmonary complications were observed. Patients with a higher volume of administered crystalloids, colloids, and total intravenous fl uids were more likely to have postoperative respiratory com- plications: the odds of postoperative respiratory complications increased by 30% with an increase of 1000 mL of crystalloid administered. The best cutoff point for total fl uids was 4165 mL, with a sensitivity of 0.8125 and specifi city of 0.7171, for postoperative pulmonary complications. A direct correlation existed between fl uids and length of stay: patients who received Ͼ4165 mL of total fl uids had an average length of stay of 3.88Ϯ4.66 days vs 2.3Ϯ3.9 days for patients who received Ͻ4165 mL of total fl uids (PϽ.0001). This study should be considered as hypothesis-generating to design a prospective trial comparing high vs low intraoperative fl uid regiments for patients undergoing spine surgery. Dr Siemionow is from the Department of Orthopaedic Surgery, University of Illinois, Chicago, Illinois; Dr Cywinski is from the Department of Anesthesia, Cleveland Clinic, Cleveland, Ohio; Dr Kusza is from the Department of Anesthesia, Centrum Medyczne Bydgoszcz, Bydgoszcz, Poland; and Dr Lieberman is from Texas Back Institute, Plano, Texas.
    [Show full text]
  • 0985.03CC Non-Mobilized Donor Consent
    Fred Hutchinson Cancer Research Center Consent to take part in a research study: 985.03CC – Non-Mobilized Donor Consent to Participate as a Donor of Non-Mobilized Peripheral Blood Mononuclear Cells for Laboratory Research and Process Development Studies. Principal Investigator: Derek Stirewalt, MD, Member, FHCRC, (206 667-5386) Investigators: Michael Linenberger, M.D., FACP Professor, Division of Hematology, UW, Robert & Phyllis Henigson Endowed Chair, Program Director, Hematology/Oncology Fellowship Medical Director, Apheresis and Cellular Therapy, SCCA, Member, FHCRC, Associate Professor of Medicine, UW, (206 667-5021); Laura Connelly Smith, Assistant Member, FHCRC, Assistant Professor, UW (206 606 -6938) Research Coordinator: Aubrey McMillan, (206) 667-3539 Emergency Phone (24 hours) UW Transplant unit 8NE: (206) 598-8902 UW Nocturnist on call provider (7:00 PM -7:00 AM): (206) 598-1062 Donor recruitment and participation: 206-667-5318 Important things to know about this study. You are invited to participate in a research study. The purpose of this research is to collect blood cells by a procedure called “leukapheresis”. Leukapheresis is a procedure that allows for a greater collection of peripheral blood cells than can be obtained by standard blood donation. Our purpose is to collect both small blood draws and larger samples of peripheral blood cells for laboratory research studies. This research may involve analysis of your genetic material called DNA and RNA. The studies may also examine other components of the cell like proteins. These analyses can be used to better understand cancer and other diseases. People who agree to join the study will be asked to attend 2 appointments over up to 30 days.
    [Show full text]
  • Leukapheresis Protocol for Nonhuman Primates Weighing Less Than 10 Kg
    Journal of the American Association for Laboratory Animal Science Vol 52, No 1 Copyright 2013 January 2013 by the American Association for Laboratory Animal Science Pages 70–77 Leukapheresis Protocol for Nonhuman Primates Weighing Less than 10 Kg Vimukthi Pathiraja, Abraham J Matar, Ashley Gusha, Christene A Huang, and Raimon Duran-Struuck* Leukapheresis is a common procedure for hematopoietic cell transplantation in adults. The main challenge in applying this procedure to human infants and small monkeys is the large extracorporeal blood volume (165 mL on average) necessary for priming the apheresis machine. This volume represents greater than 50% of the total circulating blood volume of a human neonate or small monkey. In this report, we document a safe leukapheresis protocol developed for rhesus macaques (3.9 to 8.7 kg). To avoid sensitizing donor animals undergoing leukapheresis to third-party blood products, autologous blood col- lected during the weeks prior to leukapheresis was used to volume-expand the same donor while priming the machine with saline on the day of leukapheresis. During the procedures, blood pressure was controlled by monitoring the inlet volume, and critical-care support was provided by the anesthesia team. Electrolytes and hemogram parameters were monitored intermit- tently. Overall, our research subjects underwent effective 4- to 6-h leukapheresis. A total of 9 leukapheresis procedures were performed, which yielded 1 × 109 to 6 × 109 peripheral blood mononuclear cells containing 1.1 to 5.1 × 106 CD34+ cells (assessed in 4 of 9 macaques) in a volume of 30 to 85 mL. All macaques showed decreases in Hct and platelet counts.
    [Show full text]